Business Description
CytoMed Therapeutics Ltd
ISIN : SGXZ17669631
Total Employee Number:
34Description
CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers. The company's segment include: the business of innate immune cell-based immunotherapy, pluripotent stem cell-based therapy and undertaking the research and development of immune cell and stem cell-based therapy; and the business of processing and banking of cells including cord blood stem cells, research and development on cord blood derived cell-based therapy. Geographically, the company operates in Singapore and Malaysia which is the majority revenue generator.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 4.35 | |||||
Equity-to-Asset | 0.82 | |||||
Debt-to-Equity | 0.07 | |||||
Debt-to-EBITDA | -0.13 | |||||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | 3.56 | |||||
Beneish M-Score | -0.07 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | -10.4 | |||||
3-Year EPS without NRI Growth Rate | -9.1 | |||||
3-Year FCF Growth Rate | -32.1 | |||||
3-Year Book Growth Rate | 120.5 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 55.33 | |||||
9-Day RSI | 50.53 | |||||
14-Day RSI | 48.52 | |||||
3-1 Month Momentum % | 4.13 | |||||
6-1 Month Momentum % | -1 | |||||
12-1 Month Momentum % | -47.89 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 5.17 | |||||
Quick Ratio | 5.17 | |||||
Cash Ratio | 2.96 | |||||
Days Sales Outstanding | 54.82 | |||||
Days Payable | 430.34 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -2.6 | |||||
Shareholder Yield % | -2.28 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 78.66 | |||||
Operating Margin % | -1303.16 | |||||
Net Margin % | -1223.72 | |||||
EBITDA Margin % | -1098.42 | |||||
FCF Margin % | -1350.99 | |||||
OCF Margin % | -1135.18 | |||||
ROE % | -53.74 | |||||
ROA % | -46.07 | |||||
ROIC % | -85.32 | |||||
3-Year ROIIC % | 332.12 | |||||
ROC (Joel Greenblatt) % | -99.91 | |||||
ROCE % | -49.82 | |||||
Moat Score | 2 | |||||
Tariff Resilience Score | 7 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 45 | |||||
PB Ratio | 2.31 | |||||
Price-to-Tangible-Book | 2.36 | |||||
EV-to-EBIT | -3.46 | |||||
EV-to-EBITDA | -3.85 | |||||
EV-to-Revenue | 42.32 | |||||
EV-to-FCF | -3.13 | |||||
| Price-to-Net-Current-Asset-Value | 6.6 | |||||
| Price-to-Net-Cash | 24.75 | |||||
Earnings Yield (Greenblatt) % | -28.9 | |||||
FCF Yield % | -29.18 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:GDTC
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
CytoMed Therapeutics Ltd Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 0.253 | ||
| EPS (TTM) ($) | -0.264 | ||
| Beta | -0.1788 | ||
| 3-Year Sharpe Ratio | -0.15 | ||
| 3-Year Sortino Ratio | -0.22 | ||
| Volatility % | 69.57 | ||
| 14-Day RSI | 48.52 | ||
| 14-Day ATR ($) | 0.076053 | ||
| 20-Day SMA ($) | 0.986765 | ||
| 12-1 Month Momentum % | -47.89 | ||
| 52-Week Range ($) | 0.6801 - 3.68 | ||
| Shares Outstanding (Mil) | 11.83 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
CytoMed Therapeutics Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
CytoMed Therapeutics Ltd Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-18 | In 116 days | ||
| General meeting for 2026 | 2026-08-25 | In 31 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-18 | In 24 days | ||
| Second quarter earnings results for 2026 | 2026-08-18 | In 24 days | ||
| First quarter earnings results for 2026 | 2026-07-24 | 0.88 (-2.22%) | ||
| Annual report for 2025 | 2026-03-31 | 1.03 (+3.00%) | ||
| Annual report for 2024 | 2025-04-28 | 2.28 (-1.30%) | ||
| Fourth quarter earnings results for 2024 | 2025-04-28 | 2.28 (-1.30%) |
Show
Entries
CytoMed Therapeutics Ltd Frequently Asked Questions
What is CytoMed Therapeutics Ltd(GDTC)'s stock price today?
The current price of GDTC is $0.99. The 52 week high of GDTC is $3.68 and 52 week low is $0.68.
When is next earnings date of CytoMed Therapeutics Ltd(GDTC)?
The next earnings date of CytoMed Therapeutics Ltd(GDTC) is 2026-08-18 Est..
Does CytoMed Therapeutics Ltd(GDTC) pay dividends? If so, how much?
CytoMed Therapeutics Ltd(GDTC) does not pay dividend.
Guru Commentaries on NAS:GDTC
No articles.
Press Release
Articles on CytoMed Therapeutics Ltd
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers